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0022-2836/© 2009 Elsevier Ltd. Open accSevere malaria during pregnancy is associated with accumulation of
parasite-infected erythrocytes in the placenta due to interactions between
VAR2CSA protein, expressed on the surface of infected-erythrocytes, and
placental chondroitin sulfate proteoglycans (CSPG). VAR2CSA contains
multiple CSPG-binding domains, including DBL3X and DBL6ε. Previous
structural studies of DBL3X suggested CSPG to bind to a positively charged
patch and sulfate-binding site on the concave surface of the domain. Here
we present the structure of the DBL6ε domain fromVAR2CSA. This domain
displays the same overall architecture and secondary structure as that of
DBL3X but differs in loop structures, disulfide bond positions and surface
charge distribution. In particular, despite binding to CSPG, DBL6ε lacks the
key features of the CSPG-binding site of DBL3X. Instead DBL6ε binds to
CSPG through a positively charged surface on the distal side of subdomain
2 that is exposed in intact VAR2CSA on the erythrocyte surface. Finally,
unlike intact VAR2CSA, both DBL3X and DBL6ε bind to various
carbohydrates, with greatest affinity for ligands with high sulfation and
negative charge. These studies provide further insight into the structure of
DBL domains and suggest a model for the role of individual domains in
CSPG binding by VAR2CSA in placental malaria.© 2009 Elsevier Ltd. Open access under CC BY license.Edited by R. Huber Keywords: malaria; pregnancy; PfEMP1; VAR2CSA; chondroitin sulfateIntroduction
Malaria is the most deadly parasitic disease of
mankind, causing 500 million serious cases and in
excess of 1 million deaths each year.1 While people
from endemic countries develop partial immunity
after multiple disease episodes, pregnant women
are particularly susceptible. Central to malaria
during pregnancy is accumulation of infected
erythrocytes in the intervillous space of the placenta.
The placenta provides an environment in which the
parasite can flourish, leading to maternal anemiaress:
roitin sulfate
ate A; DBL, Duffy
col; TEV, tobacco etch
nomalous dispersion.
ess under CC BY license.and causing placental inflammation and impaired
blood flow to the developing child.2–4 Malaria
during pregnancy is implicated in the death or
underweight birth of many children and kills an
estimated 75,000–200,000 fetuses each year.5
The intervillous space of the placenta contains
chondroitin sulfate proteoglycans (CSPGs). The
carbohydrate component of CSPG, chondroitin
sulfate A (CSA), acts as the primary placental
receptor for infected erythrocytes. Erythrocytes
from pregnant women bind to CSA, while those
from malaria-infected men or children do not. In
addition, soluble CSA inhibits the binding of
infected erythrocytes to placental tissue.6 These
interactions appear to be highly specific. While 4-
sulfated chondroitin structures inhibit the adhesion
of infected red blood cells to placental CSPG, other
glycosaminoglycan carbohydrates, including chon-
droitin sulfates B and C, heparin and hyaluronic
acid, do not.7–9 In addition, the percentage of 4-
sulfation alters the ability of carbohydrate to bind to
203Structural Studies of CSPG-binding by DBL Domainsinfected erythrocytes, with a combination of unsul-
fated and 4-sulfated disaccharides providing the
highest efficacy.8–11
The CSA receptor on infected erythrocytes is a
PfEMP1 protein. PfEMP1s are adhesive proteins12–14
containing multiple discrete extracellular domains,
falling mostly into two families, the cysteine-rich
interdomain region and the Duffy binding-like
(DBL) domains.15 These have important binding
properties, interacting with a variety of human
receptors.16–18 While several DBL domains from
different PfEMP1 proteins bind to CSA, VAR2CSA is
the primary CSA receptor in placental malaria.5,19–21
VAR2CSA shows upregulated expression in placen-
tal parasite isolates,22 binds to CSAwith a specificity
similar to that of infected erythrocytes23 and contains
multiple DBL domains that can bind to CSPG when
isolated.24–26 Immunity that develops following
multiple pregnancies is associated with antibodies
that bind to VAR2CSA protein21 and block CSA
binding.27–29 Indeed, antibodies raised against the
individual domains of VAR2CSA reduce the binding
of infected erythrocytes to CSA.30,31 This suggests
that the interaction between VAR2CSA and CSPG is
the principal target for development of therapeutics
to target placental malaria.
Two recent articles describe structures of the
DBL3X domain of VAR2CSA, revealing an α-helical
core with extensive loop insertions.32,33 One struc-
ture shows that a loop on the concave face of the
domain becomes ordered in the presence of sulfate
ions or disaccharide, completing the major patch of
positive charge on the domain surface.32 However,
only the sulfate ion of the disaccharide can be
observed, suggesting that other parts are disor-
dered. A second structure of DBL3X, crystallised
with longer CSA oligosaccharides, showed electronFig. 1. The structure of the DBL6ε domain of VAR2CSA. (
domains, followed by a single transmembrane helix and a cy
views of the DBL6ε domain (residues 2350–2634) with subdom
red. Green stars represent the position of residue 2480.density close to this positively charged patch, but
this density was not well-defined or continuous,
preventing model building.33 This surface was
suggested by both studies to form the CSPG-binding
site, and mutations of two lysine residues in the
positively charged patch (K1507 and K1510) re-
duced binding of the domain to CSPG.33
These studies raised many questions about the
role of DBL domains in binding to CSPG. Do
different DBL domains bind to their ligand through
a conserved site? Do individual DBL domains show
the same ligand-binding specificity as that of intact
VAR2CSA? Does VAR2CSA consist of a series of
independent, specific ligand-binding domains or do
domains combine to form a specific binding pocket?
To provide insight into some of these questions, we
determined the structure of the DBL6ε domain of
VAR2CSA and used surface plasmon resonance
measurements to investigate the CSPG-binding sites
and ligand specificity of the DBL6ε and DBL3X
domains.Results
The structure of the DBL6ɛ domain of VAR2CSA
Using a bacterial expression system, we ex-
pressed the DBL6ε domain of VAR2CSA (residues
2333–2634) from the 3D7 strain of Plasmodium
falciparum. Structure-based alignment of this se-
quence to the structure of DBL3X32 suggests that
C2480 does not form a disulfide bond with another
residue from DBL6ε. We expressed both the DBL6ε
domain and the C2480S mutant and were able to
crystallise C2480S. The structure was determineda) The VAR2CSA protein consists of six extracellular DBL
toplasmic acidic terminal sequence (ATS). (b) Orthogonal
ain 1 in yellow, subdomain 2 in orange and subdomain 3 in
204 Structural Studies of CSPG-binding by DBL Domainsusing multiple-wavelength dispersion data from a
selenomethionine derivative and was refined to
3.0 Å resolution (Fig. 1).
DBL6ε shares a similar basic fold with other DBL
domains32–35 containing a “boomerang”-shaped
α-helical core that aligns to the core of the DBL3X
structure with a root-mean-square deviation of 1.6 Å
(Fig. 2a). However, there are many differences
between DBL3X and DBL6ε. DBL6ε is shorter (302
residues compared with 359 for DBL3X) due to more
compact loop structures and a shorter subdomain 1
(Fig. 2a). DBL6ε also contains fewer disulfide bonds
than other DBL domain structures, lacking three of
the bonds that stabilise the first two subdomains of
DBL3X. In addition, the surface charge distributionFig. 2. Comparison of the structures of DBL3X and
DBL6ε. (a) Structural alignment of DBL3X [Protein Data
Bank (PDB) code 3BQK] (yellow) with DBL6ε (red)
showing the conserved α-helical scaffold and shorter loop
structures ofDBL6ε. Electrostatic surface representations of
(b) DBL6ε and (c) DBL3X. Positively charged residues
(+1.8) are blue, whereas negatively charged residues (−1.8)
are red.of the two domains differs significantly, with the
positively charged patch on the concave surface of
DBL3X (Fig. 2c), predicted to form the CSPG-
binding site,32,33 lacking in DBL6ε (Fig. 2b).
Subdomain 1 of DBL6ε consists of residues 2333–
2390 with residues 2333–2348 disordered in the
crystal. This subdomain mostly lacks secondary
structure and, unlike this region in other known
DBL domains, does not contain internal disulfide
bonds. Subdomain 2 (2391–2506) contains four
helices with several short loops. While all other
current DBL domain structures contain a disulfide
bond linking the second helix of subdomain 2 to the
linker that connects subdomains 2 and 3, this is not
present in DBL6ε, showing that this bond is not
essential for the DBL domain fold. Indeed, there are
no internal disulfide bonds in subdomain 2. The
loops in this subdomain are significantly shorter than
those of DBL3X and the loop that forms the sulfate-
binding site in the predictedCSPG-binding surface of
DBL3X (residues 1325–1341) is missing in DBL6ε.
Subdomain 3 (2507–2634) contains five disulfide
bonds and consists of two long α-helices with a third
strand completing the bundle. The distal part of the
bundle is stabilised by three disulfide bonds (C2534–
C2551, C2539–C2633 and C2555–C2631) and con-
tains a single disordered loop. The remaining two
disulfide bonds stabilise the third strand, with
C2520–C2604 linking the third strand to the first
helix of the subdomain, while C2598–C2602 stabi-
lises the end of a loop extension in the third strand.
The C2598–C2602 disulfide bond has not been
observed in other DBL domain structures. Indeed,
while the structurally characterised DBL domains
contain as many as eight disulfide bonds, only the
three at the bottom of subdomain 3 are observed in
all current structures.
Comparison of the structures of DBL3X and
DBL6ε shows differences in loop length, disulfide
bonding pattern and surface charge distribution.
Indeed, the features proposed to form the CSPG-
binding site of DBL3X, the sulfate-binding loop and
the positively charged surface, are absent in DBL6ε,
agreeing with a recent prediction based on molec-
ular modeling.36 To characterise the CSPG-binding
surface of DBL6ε, crystals were grown in the
presence of a variety of fragments of CSPG and in
the presence of sulfate ions. However, no clear
additional density due to ligand could be observed
after structure determination. We therefore devel-
oped a surface plasmon resonance assay to study
CSPG binding and used mutagenesis to map the
residues involved in the CSPG-binding sites of
DBL3X and DBL6ε.
The CSPG-binding surface of DBL3X
To map residues involved in CSPG binding we
covalently coupled human placental CSPG to a
Biacore chip. To verify the assay, we first tested the
ability of DBL3X to bind to the chip surface,
measuring its binding to a CSPG-coated surface
and subtracted the binding to a control surface that
205Structural Studies of CSPG-binding by DBL Domainslacked the ligand. This showed clear binding of
DBL3X to CSPG. As a control, we also tested the
ability of DBL1X and DBL4ɛ of VAR2CSA to bind to
CSPG. Neither DBL1X nor DBL4ɛ showed any
observable binding to CSPG at concentrations of
protein up to 100 μM (data not shown). Indeed, in
contrast to DBL3X, both DBL1X and DBL4ɛ bound
more to the control surface than to the CSPG-coated
surface.
Equilibrium analysis of saturated responses due
to binding of different concentrations of DBL3X
domain to the CSPG-coated surface (Fig. 3b) showed
half-maximal binding at a concentration of 33±13μM.
Attempts were also made to fit kinetic data to a
variety of binding models, but the dissociation
kinetics were complex and did not fit to a simple
1:1 model, suggesting heterogeneity in the interac-
tion between DBL3X and CSPG. This heterogeneity
is consistent with the absence of strong, well-defined
density in structures soaked with CSA fragments or
disaccharides.32,33To map the CSPG-binding site of DBL3X and test
predictions from previous structural studies, muta-
tions were made in individual residues that contrib-
ute to the sulfate-binding site (K1324A and R1467A)
and the positively charged patch (K1243A, K1328A,
K1504A, K1507A, K1510A and K1515A) (Fig. 3a).
An additional lysine (K1280A) was mutated as a
control. While K1280A did not inhibit the interac-
tion, all other mutations reduced binding (Fig. 3b
and Table 1). K1243A and K1515A caused the
greatest effects with more than 10-fold increases in
protein concentrations required for half-maximal
binding. These two residues lie at opposite ends of
the binding pocket, suggesting that the entire patch
plays a role in CSPG binding. Other mutations had a
smaller effect, increasing the concentration of
protein for half-maximal binding by approximately
two to fivefold. Mutations in residues that coordi-
nate the sulfate ion (K1324 and R1467) increased the
concentration that gave half-maximal binding by
about fourfold.Fig. 3. Mutagenesis of the CSPG
binding surface of DBL3X. (a) An
electrostatic representation of the
surface of the DBL3X domain show-
ing the positively charged patch and
sulfate-binding site. A bound sulfate
ion is shown in stick representation.
The side chains that contact the
sulfate (K1324 and R1467) are la-
beled, as are the other side chains
that contribute to the positive charge.
(b) Plot of the saturated Biacore
response obtained against protein
concentration for mutants of the
DBL3X domain.
Table 1.Analysis of the binding of DBL3X andmutants to
CSPG
Concentration of DBL3X that gives
half-maximal binding (μM)
Wild type 33±13
K1243A 367±50
K1324A 122±24
K1328A 89±22
R1467A 122±12
K1504A 102±14
K1507A 172±83
K1510A 193±67
K1515A 488±38
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both the positively charged patch and sulfate-
binding pocket contribute to the CSPG-binding site
of DBL3X.32,33 These residues are well conserved in
strains of the parasite from different geographical
locations and lie in a region of the domain that is
surface-exposed in intact VAR2CSA and is targeted
by antibodies from multigravid women from
endemic areas.25,37 This binding site is therefore
available for CSPG binding in infected erythrocytes
and is available for use as a CSPG-binding site
in vivo.Fig. 4. Mutagenesis of the CSPG binding surface of DBL6ε.
domain from two perpendicular directions, showing the m
saturated Biacore response obtained against protein concentraThe CSPG binding surface of DBL6ɛ
DBL6ε lacks both of the features that make up the
CSPG-binding surface of DBL3X, with a short loop
in the place of the sulfate-binding loop and no
corresponding positively charged patch. To confirm
that DBL6ε is able to bind to CSPG, we used surface
plasmon resonance, and showed clear interaction
with half-maximal binding at 80±5 μM (Fig. 4b).
We then tested the effect of mutation of different
positively charged residues on this binding. The
structure showed the presence of two major regions
of positive charge (Fig. 4a). The first contains
residues K2565 and K2567 and lies on subdomain
3. The second patch consists of residues K2392 and
K2395 and lies at the distal side of subdomain 2. We
mutated each of these residues to alanine, together
with two additional residues not in either of these
patches, K2346 and R2408. Of these surface regions,
antibody binding studies show that the patch
consisting of residues K2392 and K2395 is exposed
in VAR2CSA expressed on the surface of infected
erythrocytes, while the other mutated residues do
not show surface exposure in vivo.37
Each of these tested mutations reduced CSPG
binding (Fig. 4b and Table 2). K2346A, R2408A,
K2565A and K2567A each resulted in small decreases(a) Electrostatic representation of the surface of the DBL3X
ajor positively charged surface patches. (b) Plot of the
tion for mutants of the DBL6ε domain.
Table 2.Analysis of the binding of DBL6ε andmutants to
CSPG
Concentration of DBL6ε that gives
half-maximal binding (μM)
Wild type 80±5
K2346A 190±10
K2392A Not determined
K2395A Not determined
R2408A 151±9
K2565A 215±21
K2567A 440±60
K2395AR2408A Not determined
K2395AK2565A Not determined
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concentration by between two- and fivefold. Much
more significant effects were seen with K2392A or
K2395A. These mutants bound extremely weakly to
CSPG, and the concentration required for half-
maximal binding could not be estimated at the
protein concentrations used.Doublemutants contain-
ing K2395A together with either R2408A or K2565A
bound slightly weaker than K2395A alone.
These studies show that the positively charged
patch containing K2392 and K2395 forms the
primary CSPG-binding surface of DBL6ε. Other
residues play a minor role in CSPG binding in this in
vitro system. Several lines of evidence support the
identification of K2392 and K2395 as a CSPG-
binding site that is accessible to CSPG in vivo.
Firstly, while DBL6ε is significantly more poly-
morphic than other domains from VAR2CSA and
polymorphisms distribute over the entire surface,38
positively charged residues in this binding surface,
including K2392 and K2395, are conserved. In
addition, the surface patch containing K2392 and
K2395 is exposed in intact VAR2CSA and reacts
with antibodies from multigravid women.37 In
contrast, there is little evidence of surface-reactive
antibodies against subdomain 3, suggesting that the
small reduction in binding due to mutation of
residues on this region do not imply that this is
part of the CSPG-binding surface in vivo.
We have therefore identified a surface–exposed,
positively charged patch containing residues K2392
and K2395 as forming the CSPG-binding surface of
DBL6ε. The surface location of these residues in
intact VAR2CSA suggests that this site can also
contribute to CSPG binding in vivo. The different
location and nature of this binding pocket from the
residues used by DBL3X to bind to CSPG shows that
these two CSPG-binding DBL domains from
VAR2CSA do not interact with their ligands
through a conserved binding surface.
Carbohydrate specificity of the DBL domains
Erythrocytes infected with strains taken from
placental tissue bind selectively to 4-sulfated chon-
droitin sulfate, while other glycosaminoglycan
carbohydrates do not inhibit binding.9–11 In addi-
tion, VAR2CSA is selectively precipitated on 4-sulfated chondroitin, but not on other chondroitin
species,23 suggesting that this protein contains the
determinants for specificity. However, crystals of
DBL3X soaked with CSA disaccharides show
electron density for only the sulfate ion,32 revealing
no obvious selectivity pocket for other parts of the
carbohydrate molecule, and crystals grown in the
presence of longer CSA oligosaccharides do not
show the presence of well-defined, continuous
electron density for ligand.33 Crystals of DBL6ε
grown in the presence of different fragments of
chondroitin sulfate also show no ordered ligand. In
each case, structural studies do not reveal clear
determinants of carbohydrate specificity in single
DBL domains.
To determine whether DBL3X and DBL6ε bind
specifically to CSA, we coated a surface plasmon
resonance chip with porcine intestinal heparin. The
domains bound to this surface with half-maximal
binding at a concentration of 3.6±0.3 μM for DBL3X
(Fig. 5a) and 1.5±0.1 μM for DBL6ε (Fig. 5b).
Therefore, while heparin does not prevent the
binding of infected erythrocytes to a CSPG-coated
surface, it does bind to DBL3X and DBL6ε, with each
domain showing a greater than 10-fold stronger
binding to heparin than to CSPG. These results
agree with the recently published study by Resende
et al.,26 who also find that individual domains from
VAR2CSA, expressed in the baculovirus system, are
able to bind to heparin sulfates.
To determine whether heparin and other carbohy-
drates are able to prevent the binding of DBL3X and
DBL6ɛ to CSPG, we tested their ability to compete
for protein binding with a CSPG-coated Biacore chip
surface. Five different carbohydrates were used in
these studies, with carbohydrates obtained from the
same sources used to study the inhibition of binding
of infected erythrocytes to CSPG.10 Hyaluronic acid
from human umbilical cord is nonsulfated and
consists of alternating D-glucuronic acid and β-N-
acetylglucosamine, albeit containing approximately
25% contaminating chondroitin sulfates. Chondroi-
tin sulfates A and C consist of alternating β-
glucuronic acid and N-acetyl-β-galactosamine with
sulfates on the 4- and 6-positions of the N-
acetylgalactosamine, respectively. Dermatan sulfate
shows a similar sulfation pattern with alternating
iduronic acid and 4-sulfated β-D-acetylgalactosa-
mine. Heparin from porcine intestinal mucosa is
more highly sulfated, consisting of 2-O-sulfated
iduronic acid and 6-O-sulfated, N-sulfated glucos-
amine. These five glycosaminoglycan carbohydrates
contain differences in sulfation, negative charge and
carbohydrate backbone structure.
DBL domains were preincubated with different
concentrations of carbohydrates before passing over
the CSPG-coated Biacore chip surface and responses
were measured. All five carbohydrates inhibited
binding of DBL3X and DBL6ε, with the greatest
inhibition produced by highly sulfated heparin
structures (Fig. 5c and d). The least inhibition
was observed when unsulfated hyaluronic acid
was used, and this might be due to contaminating
Fig. 5. The carbohydrate specificity of the DBL3X and DBL6ε domains. (a and b) Plots of the saturated Biacore
response against protein concentration for the binding of (a) DBL3X and (b) DBL6ε to a heparin-coated surface. (c and d)
Competition experiments in which DBL3X (c) and DBL6ε (d) were incubated with different concentrations of (●) CSA, (■)
dermatan sulfate, (♦) chondroitin sulfate C, (○) hyaluronic acid and (□) heparin before assessment of binding to a CSPG-
coated Biacore chip surface. The specific binding to CSPG is shown as an average of three measurements.
208 Structural Studies of CSPG-binding by DBL Domainschondroitin sulfates. The chondroitin sulfates and
dermatan sulfate showed an intermediate ability to
inhibit binding, andCSAwas aweaker inhibitor than
chondroitin sulfate C or dermatan sulfate. Therefore,
individual DBL domains lack the carbohydrate-
binding specificity seen in the interaction of CSPG
with infected erythrocytes.Discussion
The binding of VAR2CSA on the surface of
infected erythrocytes to CSPG in the placenta plays
a major part in malaria during pregnancy, and an
understanding of this interaction will be valuable in
the development of therapeutics to target this form
of the disease. In this study, we present the structure
of the DBL6ε domain of VAR2CSA and character-
isation of the CSPG-binding sites of the DBL3X and
DBL6ε domains.
The DBL6ε domain shares the same basic α-helical
architecture as that of other DBL domains, with the
four α-helices of subdomain 2 and the two long α-
helices of subdomain 3 aligning closely to other
structures. Upon this structural scaffold there is
significant variation in loop length and composition,
surface charge properties and disulfide bond loca-
tions. It is these differences that lead to the greatdiversity in binding properties observed for differ-
ent DBL domains and contribute to variation that
facilitates immune evasion. However, even for two
domains, DBL3X andDBL6ε, which bind to the same
ligand, structural comparison reveals significant
differences in loop structures and surface charge
distribution.
We developed a binding assay based on surface
plasmon resonance to study the interaction of DBL
domains with CSPG. We show clear binding of
DBL3X and DBL6ε, while DBL1X and DBL4ɛ do
not bind, confirming that CSPG binding is not a
universal property of DBL domains fromVAR2CSA.
We then usedmutagenesis to mapwhich parts of the
domains form the CSPG-binding surface in each of
DBL3X and DBL6ε. DBL3X contains a single, large,
positively charged patch on the concave surface of
the domain that is completed by the folding of a
polymorphic loop (residues 1325–1333) upon bind-
ing to the sulfate moiety of a carbohydrate.32 We
confirm that both the sulfate-binding pocket and the
positively charged patch contribute to the CSPG-
binding site of DBL3X. In contrast, DBL6ε lacks both
of these surface features, and the CSPG-binding site
consists of a surface-exposed, positively charged
patch on the distal side of subdomain 2. Both binding
sites are formed from residues conserved in parasite
isolates from different geographic locations25,38 and
209Structural Studies of CSPG-binding by DBL Domainsare surface-exposed in intact infected erythrocytes.25,37
Therefore, these two DBL domains, while built on
the same α-helical scaffold, both bind to CSPG
in vitro, but both use very different surface features
for this interaction.
A striking characteristic of VAR2CSA-expressing
infected erythrocytes is their strong CSPG-binding
specificity.9,10 While it is possible that this specificity
may, in part, be due to interactions with additional
unknown receptors, one study has shown that
isolated VAR2CSA protein does show carbohydrate
specificity, as it can be precipitated with CSA but not
CSC.23 In contrast, DBL3X and DBL6ε do not
contain the determinants for selection of CSPG, but
bind more effectively to carbohydrates with in-
creased charge and sulfation. Indeed, structures of
DBL3X and DBL6ε show no clear binding pocket
that could account for this specificity, and cocrystals
reveal no well-ordered ligands. This raises questions
about whether the CSPG-binding surfaces that we
have identified on DBL3X and DBL6ε, using our
in vitro assay, contribute to ligand binding in vivo.
Indeed, DBL domains from PfEMP1 proteins that
are not upregulated in placental strains can bind to
CSPG and other carbohydrates in isolation, raising
fear of false positives.26 Nevertheless, VAR2CSA is
the PfEMP1 upregulated in placental malaria,
showing that this is the physiologically relevant
CSPG receptor. In addition, antibody depletion
studies have been used to map which parts are
exposed on infected erythrocytes, showing that the
surfaces that we have identified as CSPG-binding
sites on DBL3X and DBL6ε are both exposed on the
surface of infected erythrocytes and are therefore
available for CSPG binding in vivo.37 We have
therefore shown that DBL3X and DBL6ɛ, although
determined by crystallography to adopt the correct
DBL domain fold, do not bind specifically to CSPG.
In addition, a recent study in which each of the DBL
domains from VAR2CSA were expressed using the
baculovirus expression system confirms these find-
ings and shows that no other domains from
VAR2CSA bind specifically to CSPG.26 Therefore,
individual DBL domains from VAR2CSA do not,
alone, confer the CSPG-binding specificity of intact
erythrocytes.
These data combine to suggest that VAR2CSA
does not consist of a series of independent, specific,
CSPG-binding domains that interact with their
ligand through a conserved binding site. Instead
individual domains provide distinct surface-exposed
patches that contribute different features to CSPG
binding. Thesepositively chargedpatches and sulfate-
binding sites, contributed by different domains, are
surface-exposed on the infected erythrocyte and are
available for CSPG binding in vivo. How these
domains come together to generate the specific
CSPG-binding site observed in VAR2CSA is uncer-
tain. However, several pieces of evidence suggest that
VAR2CSAdoes not consist of a series ofDBLdomains
linked through flexible linkers, but that it adopts
higher-order structure. Large parts of VAR2CSA,
including the linkers between DBL domains, are notpolymorphic in isolates from pregnant women from
different geographical locations.25,37 This suggests
that they are not under selection pressure to vary, as
would be expected if exposed to the immune system.
In addition, only restricted parts of the domain
surfaces are accessible to antibodies from pregnant
women.37 This all leads to a model in which the
domains of VAR2CSA are organised in three-
dimensions, positioning different surfaces involved
in CSPG binding to form a specific binding pocket. A
full understanding of the binding mechanism of
VAR2CSA for CSPGwill therefore require structures
of larger fragments of VAR2CSA showing how these
domains fit together. Nevertheless, antibodies raised
against isolated domains, including DBL6ε, have
been shown to inhibit binding of infected erythro-
cytes to CSPG,30,31 suggesting that therapeutics
targeting a single domain can be effective. Therefore,
information about the exposed binding surfaces
contributed by DBL3X and DBL6ε to CSPG binding
can provide valuable guidance for rational develop-
ment of therapeutics.
Materials and Methods
Expression, mutagenesis and purification of the
DBL3X domain
The DBL3X domain of VAR2CSA (accession codes
AY372123 and AAQ73926) was cloned from A4 strain
genomic DNA with a six-histidine residue tag at the N-
terminus as described in Ref. 39. Single point mutations
were made using a polymerase chain reaction-based
mutagenesis protocol. The forward primers were K1243A
(AAAATATTTCCAGGTGCAGGAGGCGAGAAACAA),
K1280A (AGTTATGGG ATGCAAGTTATGGTGGAA),
K13 2 4A (CAGCAATTATATCAGCAAATGA-
TAAAAAAGG), K1328A (CAAAAAATGATAAAGCA
GGACAAAAAGGAAAA), R1467A (GTATAGAAC-
GATTA GCATATGAACAAAATATA), K1504A (GGAG-
CATGTAAAAGAGCATGTGAAAAATATAA), K1507A
(AAAAGAAAAT GTGAAGCATATAAAAAATATATT),
K1510A (GTGAAAAATATAAAGCATATATTTCT
GAAA) and K1515A (AATATATTTCTGAAGCAAAA-
CAAGAATGGGA). Reverse primers were the reverse
complement of the forward primers. Mutagenesis was
carried out as described for the Quikchange mutagenesis
method (Stratagene) and plasmids were checked by DNA
sequencing. Protein was expressed and purified as
described in Ref. 39, and circular dichroismmeasurements
were used to confirm that mutations had not altered the
structure of the domain.
Cloning, expression and purification of the
DBL1X, DBL4ɛ and DBL6ɛ domains
The DBL1X (residues 81–428, accession code
AY372123), DBL4ε (residues 1595–1909, accession code
AY372123) and DBL6ε (residues 2333–2634, accession
codeAE014844.1) domains of VAR2CSAwere cloned from
genomic DNA and ligated into the BamHI–NheI site of a
modified pEt15b plasmid (Novagen) in-frame with the
tobacco etch virus (TEV) cleavage site.39
The C2480S mutant of DBL6ɛ was made using a
polymerase chain reaction-based mutagenesis protocol
210 Structural Studies of CSPG-binding by DBL Domainsusing forward primer TGGG AATCTATGTTATCTGGA-
TACAAACATGCC and the reverse complement. Muta-
genesis was carried out as described for the Quikchange
mutagenesis method (Stratagene) and confirmed by DNA
sequencing.
The plasmids were transformed into Origami B Escher-
ichia coli (Novagen) containing the pRIG plasmid.40 The
cells were grown in 2xYT medium at 37 °C to reach an
optical density of 1.4 at 600 nm and were then induced
with 1 mM IPTG. The expression of the soluble His-tagged
protein was allowed to take place overnight at 25 °C.
Cells were harvested by centrifuge and resuspended in
buffer 1 [20 mM Tris (pH 8.0), 0.3 M NaCl, 10 mM
imidazole, 0.5% Triton X-100] and lysed by sonication. The
cell lysate was centrifuged for 30 min at 45,000g and
purified by affinity chromatography using Ni–NTA
Sepharose (Qiagen). The supernatant was loaded onto a
Ni–NTA affinity column, washed with buffer 1 and buffer
2 [20 mMTris (pH 8.0), 0.5 MNaCl, 10 mM imidazole] and
eluted with 20 mM Tris (pH 8.0), 0.1 M NaCl and 0.2 M
imidazole.
Buffer exchange of the protein into 20 mM phosphate
(pH 7.4), 150 mM NaCl, 3 mM reduced glutathione and
0.3 mM oxidized glutathione was done prior to the
addition of 1 mg of TEV protease per 10 mg of protein. The
cleavage reaction was incubated overnight at room
temperature. Cleaved protein was passed through a Ni–
NTA affinity column (to remove uncleaved protein and
TEV protease), followed by a Q-Sepharose column (GE
Healthcare) and gel filtration using a Superdex 200 16/60
column (GE Healthcare) with buffer [20 mM Tris (pH 8.0),
50 mM NaCl]. The protein was concentrated to 10 mg/ml
with an Amicon Ultra centrifugal filter device (10,000 Da
molecular mass cutoff). Each litre of bacterial culture
yielded 2.5–5.0 mg of purified protein.
Mutagenesis of DBL6ɛ
Site-directed mutagenesis was performed with a poly-
merase chain reaction-based mutagenesis protocol using
primers K2346A (GTTAATATGAAAGCAAATAATGAT-
GATA), K2392 (AAAAGAGATCCTGCATTGTTTAAA-
GAT), K2395 (CCTAAATTGTTTGCAGATTTCA TTTAT),
K2408A (CTGAAGTTGAAGCGTTAAAAAAAGTA-
TATG), K2565A (TTTATT TTAATAGCAAAAAAGGAG-
TATC) andK2567A (TTAATAAAAAAAGCGGAGTATCA
GTCAC). Reverse primers were the reverse complement of
the forward primers. Mutagenesis was carried out as
described for the Quikchange mutagenesis method (Strata-
gene). Plasmids were checked by DNA sequencing and
protein was expressed and purified as above. Double
mutations were carried out sequentially.Table 3. Data collection statistics
Se-D
Peak Ed
Beamline BM14
Space group P43
Unit cell parameter (Å) a, b=63.76
Resolution limit (Å) 83.3
Wavelength (Å) 0.97855 0.97
Rmrg (%) 8.2 (48.0) 9.6 (
I/σ(I) 16.0 (3.9) 24.4
Completeness (%) 99.5 (99.4) 99.5
Multiplicity 6.6 (6.8) 6.5
Anomalous completeness 99.9 (99.6) 99.9
Anomalous multiplicity 3.7 (3.6) 3.7Production of selenomethionine-labeled DBL6ɛ
domain
Cells initially grown in 2xYT medium to an optical
density of 1.4 at 600 nm and pelleted before resuspension
in M9 media (20% glucose, 40 mM Na2HPO4, 20 mM
KH2PO4, 20 mM NH4Cl, 8.5 mM NaCl, 1 mM MgSO4,
100 mg/l each of L-lysine, L-phenylalanine and L-
threonine and 50 mg/l each of L-isoleucine, L-leucine,
L-valine and L-selenomethionine). They were incubated
at 37 °C for a further 1.5 h, induced with 1 mM IPTG
and incubated overnight at 25 °C to allow expression to
take place. The selenomethionine-labeled protein was
purified as above.
Crystallisation of the DBL6ɛ domain
Crystals were grown using the hanging-drop vapour-
diffusion method by mixing 1 μl of protein solution with
1 μl of reservoir solution and 0.5 μl of additive solution
(0.01 M glutathione reduced, 0.01 M glutathione oxidized)
and equilibrating against 1 ml of reservoir solution.
Crystals grew in 18–28% polyethylene glycol (PEG)
4000, 0.1 M Tris (pH 6.0–8.0) and 0.1–0.7 M sodium
acetate. They were visible after 4–6 days and continued to
grow for 10–14 days. Crystals of selenomethionine-labeled
protein were grown in the same condition as the native
and appeared within 4–6 days. For cocrystallisation, CSA
fragments were prepared as described in Ref. 32. CSA
fragments (2mer, 8mer and 12mer) were incubated with
the DBL6ε domain protein with molar ratios of 1:10 for 2 h
at room temperature prior to setting up droplets. Crystals
from cocrystallisation formed in the same conditions as
native crystals.
Data collection and structure determination of
the DBL6ɛ domain
The selenomethionine-labeled crystals for multiple-
wavelength anomalous dispersion (MAD) experiments
were grown in 26% PEG 4000, 0.1 M Tris (pH 8.0) and
0.5M sodium acetate. Theywere cryoprotected by transfer
into 25% glycerol, 34% PEG 4000, 0.1 M Tris (pH 8.0),
0.5 M sodium acetate, 200 mM ascorbate and 0.5 mM β-
mercaptoethanol and flash-frozen in liquid nitrogen.
Diffraction data were collected to 3.0 Å at 100 K on
beamline BM14 at the European Synchrotron Radiation
Facility (ESRF, Grenoble, France). Native data sets were
also collected at 100 K on beamline I02 at the Diamond
Light Source using crystals grown in 30% PEG 4000, 0.1 M
Tris (pH 8.0) and 0.35 M sodium acetate.BL6ε
Native DBL6εge Remote
ESRF I02 Diamond
212 P43212
, c=333.48 a, b=62.94, c=334.27
3–3.0 111.11–3.0
871 0.91999 0.9200
64.1) 10.9 (61.4) 10.2 (60.2)
(5.2) 25.1 (4.9) 14.2 (2.9)
(99.4) 99.5 (99.7) 99.9 (100)
(6.8) 6.5 (6.8) 5.8 (6.2)
(99.7) 99.4 (99.9)
(3.6) 3.6 (3.7)
Table 4. X-ray refinement statistics of DBL6ε
RMSD bond lengths (Å) 0.069
RMSD bond angles (°) 0.893
Reflection used for refinement (work/free) 14481/2038
Rwork (%) 28.9
Rfree (%) 32.5
No. of protein residues 584
Ramachandran plot
Allowed region (%) 83.6
Additional allowed region (%) 16.4
Generously allowed region (%) 0
Disallowed region (%) 0
211Structural Studies of CSPG-binding by DBL DomainsNative and MAD data were processed using
MOSFLM41 and SCALA42 from the CCP4 suite43 and
were consistent with a primitive tetragonal lattice.
Systematic absences in the 00l and h00, 0l0 reflections
indicated that the crystals belong to space group P43212.
The structure was determined using MAD phasing with
data from a selenium derivative. The asymmetric unit of
the crystal contained two molecules, and 18 Se sites were
found and refined using autoSHARP.44 MAD phases,
following density modification, were used to calculate an
initial map that was used for model building in Coot.45 The
structure was refined against native data (100° of data at
3.2 Å) using TLS refinement in Refmac546 with 5%
reflections kept excluded for Rfree evaluation. Data proces-
sing and structure refinement statistics are outlined in
Tables 3 and 4.
Surface plasmon resonance measurements
Measurements were performed on a Biacore 2000
instrument with a constant flow rate of 30 μl/min.
Placental CSPG was obtained from MR4 (deposited by
C. Gowda) and coupled to the surface of a CM5 chip
(Biacore) using the amine coupling protocol as recom-
mended by the manufacturer. Briefly, channels 1 and 2
were treated with a 1:1 mixture of 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide and N-hydroxysuccinimide
(Biacore). Placental CSPG was dissolved to a concentra-
tion of 100 μg/ml in 10 mM sodium acetate (pH 5.0) and
flowed through channel 2 until the response increased by
400 RU. The remaining reactive groups on both surfaces
were then blocked with ethanolamine.
Proteins were equilibrated using PD10 columns (Amer-
sham Biosciences) into HBS buffer [10 mMHepes (pH 7.4),
150 mM NaCl, 50 μM ethylenediaminetetraacetic acid,
0.05% Tween 20] and concentrated for Biacore analysis.
Both channels were equilibrated with HBS buffer before
injection of purified DBL domain protein. The level of
specific binding was obtained from a subtraction of the
response from channel 2 from that of channel 1. After each
injection, both channels were regenerated with a 30-μl
injection of 5 mM NaOH, followed by a 30-μl injection of
5 M NaCl. This procedure led to recovery of the original
baseline and regenerated a CSPG surface that could bind
reproducibly to subsequent injections of DBL3X protein.
Data were analysed using the BIAevaluation software
to obtain maximum response values for saturated curves.
These were plotted against the concentration of protein
using Prism 5.01 (GraphPad Software Inc., CA) and fitted
to a single-site binding model, allowing determination
of the concentration that gave half-maximal response.
Errors are the given values with 95% confidence. The
BIAevaluation software was used to analyse the kinetics of
association and dissociation.Carbohydrate competition experiments
Carbohydrates were obtained from Sigma: CSA from
bovine trachea (C9819), chondrotin sulfate C from shark
cartilage (C4384), dermatan sulfate from porcine intestinal
mucosa (C3788), heparin from porcine intestinal mucosa
(H9399) and hyaluronic acid from human umbilical cord
(53750). Each carbohydrate was dissolved in HBS to 1mg/
ml and filtered through a 0.2-μm membrane (Sartorius).
These stocks were mixed with DBL domain to produce
samples with a final concentration of 5 μM for DBL3X or
15 μM for DBL6ε and a range of carbohydrate concentra-
tions (25–500 mM) in HBS. These were incubated for a
minimum of 30 min before Biacore measurements were
taken as described above.
Heparin binding studies
Porcine intestinal heparin was dissolved to 5 mg/ml in
20mM sodiumphosphate (pH 7.4) and 150mMNaCl. One
milliliter of this heparin solution was incubated with 25 μl
of 50 mM biotin-hydrazide (Pierce) and 15 μl of 1-ethyl-3-
(3-dimethylaminopropyl) (100 mg/ml) for 2 h at 25°C. The
heparin was then dialysed overnight into 20 mM sodium
phosphate (pH 7.4) and 150 mM NaCl and 100 μl was
injected over flow cell 2 of a streptavidin-coated SA chip
(Biacore).
Channels 1 and 2 of this chip were equilibrated with
HBS buffer before injection of purified DBL3X or DBL6ε
domain. The level of specific binding was obtained from a
subtraction of the response from channel 2 from that of
channel 1. After each injection, both channels were
regenerated with a 30-μl injection of 2 M NaCl, restoring
the signal to original levels. Data were analysed as above.
PDB accession numbers
Coordinates and structure factors have been deposited
in the PDB with accession number 2wau.Acknowledgements
We thank Ali Salanti, Madeleine Dahlback, Thor
Theander and Lars Hviid for valuable discussions
and Mario Bumann at beamline BM14 at the ESRF,
Grenoble, and Mark Williams at beamline I02 at the
DiamondLight Source for help duringdata collection.
M.K.H. is a Royal Society University Research Fellow
and this work was supported by grants from the
Royal Society and theWellcome trust. PKwas funded
by a scholarship from the Royal Thai Government.
References
1. Breman, J. G., Egan, A. & Keusch, G. T. (2001). The
intolerable burden of malaria: a new look at the
numbers. Am. J. Trop. Med. Hyg. 64, iv–vii.
2. Brabin, B. J., Romagosa, C., Abdelgalil, S., Menéndez,
C., Verhoeff, F. H., McGready, R. et al. (2004). The sick
placenta-the role of malaria. Placenta, 25, 359–378.
3. Dorman, E. K., Shulman, C. E., Kingdom, J., Bulmer,
J. N., Mwendwa, J., Peshu, N. & Marsh, K. (2002).
Impaired uteroplacental blood flow in pregnancies
212 Structural Studies of CSPG-binding by DBL Domainscomplicated by Falciparum malaria. Ultrasound Obstet.
Gynecol. 19, 165–170.
4. Suguitan, A. L., Leke, R. G., Fouda, G., Zhou, A.,
Thuita, L., Metenou, S. et al. (2003). Changes in the
levels of chemokines and cytokines in the placentas of
women with Plasmodium falciparum malaria. J. Infect.
Dis. 188, 1074–1082.
5. Hviid, L. & Salanti, A. (2007). VAR2CSA and
protective immunity against pregnancy-associated
Plasmodium falciparum malaria. Parasitology, 134,
1871–1876.
6. Fried, M. & Duffy, P. E. (1996). Adherence of
Plasmodium falciparum to chondroitin sulfate A in the
human placenta. Science, 272, 1502–1504.
7. Achur, R.N., Valiyaveettil,M.,Alkhalil, A.,Ockenhouse,
C. F. & Gowda, D. C. (2000). Characterization of
proteoglycans of human placenta and identification
of unique chondroitin sulfate proteoglycans of the
intervillous spaces that mediate the adherence of
Plasmodium falciparum-infected erythrocytes to the
placenta. J. Biol. Chem. 275, 40344–40356.
8. Acher, R. N., Valiyaveettil, H. & Gowda, D. C. (2003).
The low sulfated chondroitin sulfate proteoglycans of
human placenta have sulfate group-clustered domains
that can efficiently bindPlasmodium falciparum-infected
erythrocytes. J. Biol. Chem. 278, 11705–11713.
9. Fried, M., Lauder, R. M. & Duffy, P. E. (2000).
Plasmodium falciparum: adhesion of placental isolates
modulated by the sulfation characteristics of the
glycosaminoglycan receptor. Exp. Parasitol. 995, 75–78.
10. Alkhalil, A., Achur, R. N., Valiyaveettil, M., Ocken-
house, C. F. & Gowda, D. C. (2000). Structural
requirements for the adherence of Plasmodium falci-
parum-infected erythrocytes to chondroitin sulfate
proteoglycans of human placenta. J. Biol. Chem. 275,
40357–40364.
11. Chai, W., Beeson, J. G. & Lawson, A. M. (2002). The
structural motif in chondroitin sulfate for adhesion of
Plasmodium falciparum-infected erythrocytes com-
prises disaccharide units of 4-O-sulfated and non-
sulfated N-acetylgalactosamine linked to glucuronic
acid. J. Biol. Chem. 277, 22438–22446.
12. Kraemer, S. M. & Smith, J. D. (2006). A family affair:
var genes, PfEMP1 binding, andmalaria disease. Curr.
Opin. Microbiol. 9, 374–378.
13. Smith, J. D., Chitnis, C. E., Craig, A. G., Roberts, D. J.,
Hudson-Taylor, D. E., Peterson, D. S. et al. (1995).
Switches in expression of Plasmodium falciparum var
genes correlate with changes in antigenic and cytoad-
herent phenotypes of infected erythrocytes. Cell, 82,
101–110.
14. Su, X. Z., Heatwole, V. M., Wertheimer, S. P., Guinet,
F., Herrfeldt, J. A., Peterson, D. S. et al. (1995). The
large diverse gene family var encodes proteins
involved in cytoadherence and antigenic variation of
Plasmodium falciparum-infected erythrocytes. Cell, 82,
89–100.
15. Gardner, M. J., Hall, N., Fung, E., White, O., Berriman,
M., Hyman, R.W. et al. (2002). Genome sequence of the
humanmalaria parasite Plasmodium falciparum.Nature,
419, 498–511.
16. Rowe, J. A., Moulds, J. M., Newbold, C. I. & Miller,
L. H. (1997). P. falciparum rosetting mediated by a
parasite-variant erythrocyte membrane protein and
complement-receptor 1. Nature, 388, 292–295.
17. Smith, J. D., Kyes, S., Craig, A. G., Fagan, T.,
Hudson-Taylor, D., Miller, L. H. et al. (1998). Analysis
of adhesive domains from the A4VAR Plasmodium
falciparum erythrocyte membrane protein-1 identifiesa CD36 binding domain. Mol. Biochem. Parasitol. 97,
133–148.
18. Smith, J. D., Craig, A. G., Kriek, N., Hudson-Taylor,
D., Kyes, S., Fagan, T. et al. (2000). Identification of a
Plasmodium falciparum intercellular adhesion mole-
cule-1 binding domain: a parasite adhesion trait
implicated in cerebral malaria. Proc. Natl Acad. Sci.
USA, 97, 1766–1771.
19. Rowe, J. A. & Kyes, S. (2004). The role of Plasmodium
falciparum var genes in malaria in pregnancy. Mol.
Microbiol. 53, 1011–1019.
20. Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T.,
Sowa, M. P., Arnot, D. E. et al. (2003). Selective
upregulation of a single distinctly structured var gene
in chondroitin sulphate A-adhering Plasmodium falci-
parum involved in pregnancy-associated malaria.Mol.
Microbiol. 49, 179–191.
21. Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A.,
Barfod, L., Magistrado, P. et al. (2004). Evidence for the
involvement of VAR2CSA in pregnancy-associated
malaria. J. Exp. Med. 200, 1197–1203.
22. Viebig, N. K., Gamain, B., Scheidig, C., Lépolard, C.,
Przyborski, J., Lanzer, M. et al. (2005). A single
member of the Plasmodium falciparum var multigene
family determines cytoadhesion to the placental
receptor chondroitin sulphate A. EMBO Rep. 6,
775–778.
23. Beeson, J. G., Andrews, K. T., Boyle, M., Duffy, M. F.,
Choong, E. K., Byrne, T. J. et al. (2007). Structural basis
for binding of Plasmodium falciparum erythrocyte
membrane protein 1 to chondroitin sulfate and
placental tissue and the influence of protein poly-
morphisms on binding specificity. J. Biol. Chem. 282,
22426–22436.
24. Gamain, B., Trimnell, A. R., Scheidig, C., Scherf, A.,
Miller, L. H. & Smith, J. D. (2005). Identification of
multiple chondroitin sulfate A (CSA)-binding
domains in the var2CSA gene transcribed in CSA-
binding parasites. J. Infect. Disease, 191, 1010–1013.
25. Dahlbäck, M., Rask, T. S., Andersen, P. H., Nielsen, M.
A., Ndam, N. T., Resende, M. et al. (2006). Epitope
mapping and topographic analysis of VAR2CSA
DBL3X involved in P. falciparum placental sequestra-
tion. PLoS Pathog, e124, 2.
26. Resende, M., Ditlev, S. B., Nielsen, M. A., Bodevin, S.,
Bruun, S., Pinto, V. V. et al. (2009). Chondroitin
sulphate A (CSA)-binding of single recombinant
Duffy-binding-like domains is not restricted to
Plasmodium falciparum erythrocyte membrane protein
1 expressed by CSA-binding parasites. Int. J. Parasitol.
39, 1195–1204.
27. Fried, M., Nosten, F., Brockman, A., Brabin, B. J. &
Duffy, P. E. (1998). Maternal antibodies block malaria.
Nature, 395, 851–852.
28. O'Neil-Dunne, I., Achur, R. N., Agbor-Enoh, S. T.,
Valiyaveettil, M., Naik, R. S., Ockenhouse, C. F. et al.
(2001). Gravidity-dependent production of antibodies
that inhibit binding of Plasmodium falciparum-infected
erythrocytes to placental chondroitin sulfate proteo-
glycan during pregnancy. Infect. Immun. 69, 7487–7492.
29. Ricke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D.,
Riley, E. M., Theander, T. G. & Hviid, L. (2000).
Plasma antibodies from malaria-exposed pregnant
women recognize variant surface antigens on Plasmo-
dium falciparum-infected erythrocytes in a parity-
dependent manner and block parasite adhesion to
chondroitin sulfate A. J. Immunol. 165, 3309–3316.
30. Fernandez, P., Viebig, N., Dechavanne, S., Lépolard,
C., Gysin, J., Scherf, A. & Gamain, B. (2008). Var2CSA
213Structural Studies of CSPG-binding by DBL DomainsDBL6-epsilon domain expressed in HEK293 induces
limited cross-reactive and blocking antibodies to CSA
binding parasites. Malar. J. 7, 170.
31. Nielsen, M. A., Pinto, V. V., Resende, M., Dahlbäck, M.,
Ditlev, S. B., Theander, T. G. & Salanti, A. (2009).
Induction of adhesion-inhibitory antibodies against
placentalPlasmodium falciparumparasites byusing single
domains of VAR2CSA. Infect Immun, 77, 2482–2487.
32. Higgins, M. K. (2008). The structure of a chondroitin
sulfate-binding domain important in placentalmalaria.
J. Biol. Chem. 283, 21842–21846.
33. Singh, K., Gittis, A. G., Nguyen, P., Gowda, D. C.,
Miller, L. H. & Garboczi, D. N. (2008). Structure of the
DBL3x domain of pregnancy-associated malaria
protein VAR2CSA complexed with chondroitin
sulfate A. Nat. Struct. Mol. Biol. 15, 932–938.
34. Singh, S. K., Hora, R., Belrhali, H., Chitnis, C. E. &
Sharma, A. (2006). Structural basis for Duffy recogni-
tion by themalaria parasiteDuffy-binding-like domain.
Nature, 439, 741–744.
35. Tolia, N. H., Enemark, E. J., Sim, B. K. & Joshua-Tor, L.
(2005). Structural basis for the EBA-175 erythrocyte
invasion pathway of the malaria parasite Plasmodium
falciparum. Cell, 122, 183–193.
36. Gill, J., Chitnis, C. E. & Sharma, A. (2009). Structural
insights into chondroitin sulphate A binding Duffy-
binding-like domains from Plasmodium falciparum:
implications for intervention strategies against pla-
cental malaria. Malar. J. 8, 67.
37. Bockhorst, J., Lu, F., Janes, J. H., Keebler, J., Gamain,
B., Awadalla, P. et al. (2007). Structural polymorphism
and diversifying selection on the pregnancy malaria
vaccine candidate VAR2CSA. Mol. Biochem. Parasitol.
155, 103–112.38. Anderson, P., Nielsen, M. A., Resende, M., Rask, T. S.,
Dahlbäck, M., Theander, T. et al. (2008). Structural
insight into epitopes in the pregnancy-associated
malaria protein VAR2CSA. PLoS Pathog. e42, 4.
39. Higgins, M. K. (2008). Overproduction, purification
and crystallization of a chondroitin sulfate A-binding
DBL domain from a Plasmodium falciparum var2csa-
encoded PfEMP1 protein. Acta Crystallogr., Sect. F:
Struct. Biol. Cryst. Commun. 64, 221–223.
40. Baca, A. M. & Hol, W. G. J. (2000). Overcoming codon
bias: a method for high-level overexpression of
Plasmodium and other AT-rich parasite genes in
Escherichia coli. Int. J. Parasitol. 30, 113–118.
41. Leslie, A. G. (2006). The integration of macromolec-
ular diffraction data. Acta Crystallogr., Sect. D; Biol.
Crystallogr. 62, 48–57.
42. Evans, P. R. (1993). Data reduction. In Proceedings of
the CCP4 Study Weekend. Data Collection and Processing
(Sawyer, L., Isaacs, N. & , S., eds), pp. 114–122,
Daresbury Laboratory, Warrington, UK.
43. Collaborative Computational project, Number 4
(1994). The CCP4 suite: programs for protein
crystallography. Acta. Cryst., Sect. D: Biol. Crystallogr.
50, 760–763.
44. Vonrhein, C., Blanc, E., Roversi, P. & Bricogne, G.
(2007). Automated structure solution with auto-
SHARP. Methods Mol. Biol. 364, 213–215.
45. Emsley, P. & Cowtan, K. (2004). Coot: model-building
tools for molecular graphics. Acta Crystallogr., Sect. D:
Biol. Crystallogr. 60, 2126–2132.
46. Murshudov, G. N., Vagin, A. A. & Dodson, E. J.
(1997). Refinement of macromolecular structures by
the maximum-likelihood method. Acta Crystallogr.,
Sect. D: Biol. Crystallogr. 53, 225–240.
